FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Manufacturer

Country

Certificates

FDA

Document

No Title 0.29 MB
Registration Date 27 Jul 2016
Share

SUTENT ®

Medicine Pharmaceuticals Product Number : 0069-0770-38

Pancreatic Neuroendocrine Tumors

Drug Information

Generic
SUNITINIB MALATE
NDC Code
0069-0770-38
Drug Class
Multikinase inhibitors
Therapeutic Class
Antineoplastic
Dosage form
Capsule
Route of Administration
Oral
Therapeutic Area
1.Pancreatic neuroendocrine tumors

Indication

Sutent is indicated for  Gastrointestinal Stromal Tumor (GIST) Advanced Renal Cell Carcinoma (RCC) Advanced Pancreatic Neuroendocrine Tumors (pNET)

Benefit

Sutent® is currently administrated orally as a capsule (and absorbed through the gastrointestinal tract), hence it poses no toxicity to the mouth cavity if integrated into the biotech start-up’s drug delivery platform (For about 9 years, SUTENT has been a widely used therapy in the treatment of advanced RCC and certain patients with GIST.* SUTENT may help slow the spread of cancer. SUTENT may also help shrink some tumors.)